Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin.

被引：0
|
作者：
McHutchison, JG
Davis, GL
Esteban-Mur, R
Poynard, T
Ling, MH
Garaud, JJ
Albrecht, J
机构：
[1] Scripps Clin, La Jolla, CA USA
[2] Univ Florida, Coll Med, Gainesville, FL USA
[3] Hosp Gen Valle Hebron, Barcelona, Spain
[4] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
[5] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
281
引用
收藏
页码：244A / 244A
页数：1
相关论文
共 50 条
  • [31] Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
    Roomer, Robert
    Bergmann, Jilling F.
    Boonstra, Andre
    Hansen, Bettina E.
    Haagmans, Bart L.
    Kwadijk-de Gijsel, Sonja
    van Vuuren, Anneke J.
    de Knegt, Robert J.
    Janssen, Harry L. A.
    ANTIVIRAL THERAPY, 2012, 17 (03) : 509 - 517
  • [32] Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children
    Pawlowska, Malgorzata
    Pilarczyk, Malgorzata
    Halota, Waldemar
    MEDICAL SCIENCE MONITOR, 2010, 16 (12): : CR616 - CR621
  • [33] Interferon a-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon
    Min, AD
    Jones, J
    Esposito, S
    Lebovics, E
    Klion, F
    Jacobson, I
    Goldman, I
    Geders, J
    Tobias, H
    Branch, A
    Bodenheimer, H
    HEPATOLOGY, 1998, 28 (04) : 286A - 286A
  • [34] Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy:: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy).
    Pimstone, NR
    Canio, JB
    Chiang, MH
    Kokosinski, J
    Powell, JS
    Saicheur, T
    Sheykhzadeh, PI
    Yu, AS
    GASTROENTEROLOGY, 2001, 120 (05) : A568 - A568
  • [35] Consensus interferon in combination with ribavirin for hepatitis C patients with nonresponse or relapse to interferon alpha and ribavirin.
    Buggisch, P
    Hinrichsen, H
    Hueppe, D
    Reiser, M
    Kueppers, H
    Wursthorn, K
    Sterneck, M
    HEPATOLOGY, 2001, 34 (04) : 590A - 590A
  • [36] Interferon alfacon-1 and ribavirin versus interferon α-2b and ribavirin in the treatment of chronic hepatitis C
    Sjogren, MH
    Sjogren, R
    Holtzmuller, K
    Winston, B
    Butterfield, B
    Drake, S
    Watts, A
    Howard, R
    Smith, M
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (04) : 727 - 732
  • [37] Interferon Alfacon-1 and Ribavirin Versus Interferon α-2b and Ribavirin in the Treatment of Chronic Hepatitis C
    Maria H. Sjogren
    Robert Sjogren
    Kent Holtzmuller
    Bradley Winston
    Betty Butterfield
    Stanley Drake
    Amber Watts
    Robin Howard
    Milton Smith
    Digestive Diseases and Sciences, 2005, 50 : 727 - 732
  • [38] Interferon alfa 2b and ribavirin combination therapy for patients with chronic viral hepatitis C failing interferon therapy
    Galica, M
    Alhajjar, B
    Salen, G
    Dyrszka, H
    Sanghavi, B
    Eskreis, D
    HEPATOLOGY, 1998, 28 (04) : 709A - 709A
  • [39] Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
    Meissner, Eric G.
    Nelson, Amy
    Marti, Miriam
    Masur, Henry
    Osinusi, Anu
    Kottilil, Shyam
    OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (01):
  • [40] The effect of induction pegylated interferon alfa 2b and ribavirin on early virologic response in genotype 1 chronic hepatitis C
    Lawitz, EJ
    Harrison, SA
    Cantu, NS
    Davis, M
    Perkel, M
    Vemuru, R
    Nguyen, T
    Kadakia, S
    Ganeshappa, KP
    Diamond, K
    Matossian, H
    Box, TD
    Ghandour, E
    GASTROENTEROLOGY, 2004, 126 (04) : A723 - A723
12345